EP Patent

EP3972630A1 — Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides

Assigned to MedImmune Ltd · Expires 2022-03-30 · 4y expired

What this patent protects

Provided herein are coformulations comprising cyclodextrin that allow for concurrent, subcutaneous administration of sodium glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, and incretin peptides, such as GLP-1/Glucagon dual agonist peptides.

USPTO Abstract

Provided herein are coformulations comprising cyclodextrin that allow for concurrent, subcutaneous administration of sodium glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, and incretin peptides, such as GLP-1/Glucagon dual agonist peptides.

Drugs covered by this patent

Patent Metadata

Patent number
EP3972630A1
Jurisdiction
EP
Classification
—
Expires
2022-03-30
Drug substance claim
No
Drug product claim
No
Assignee
MedImmune Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.